Oral vesicles/ulcers, vesicular rash on palms and soles
Differentiating: vesicles not present in roseola
Scarlet fever
ICD-10 A38.9
Sandpaper rash, pharyngitis, strawberry tongue, rash concurrent with fever
Differentiating: rash in roseola appears after fever; no pharyngitis pattern
Other important differentials
Drug eruption
ICD-10 L27.0
Temporal relationship to new medication introduction
Often receives concurrent antibiotics during febrile phase, obscuring diagnosis
Differentiating from roseola
Pruritus more common in drug rash; absence of fever-rash sequence
Urticaria
Most common cause of acute pediatric exanthem presenting to ED
Wheals, pruritus, blanching
No fever-to-rash sequence
UTI (occult fever source in pre-eruptive phase)
ICD-10 N39.0
Common occult source of fever in infants
Urinalysis and urine culture recommended per AAP guidelines in febrile infants <24 months
Laboratory Tests
Routine labs
Complete blood count
Characteristic pattern in primary HHV-6 infection
Leukopenia (mean WBC 8,900/mm3)
Lymphopenia
Neutropenia
Clinical utility
Distinguishes HHV-6 from typical bacterial infection (bacterial: leukocytosis)
Not required in well-appearing child with classic rash presentation
Urinalysis
Indication per AAP guidelines
Febrile infants <24 months without clear fever source
Obtain during the pre-eruptive febrile phase before diagnosis is established
Interpretation
Positive UA does not exclude concurrent HHV-6; both can coexist
CRP and procalcitonin
Risk stratification for bacterial superinfection
CRP mildly elevated in HHV-6 but typically lower than bacterial infection
Procalcitonin may be elevated in HHV-6 but lower than in bacteremia
Use in combination with clinical picture, not as sole decision tool
Labs for severe or atypical presentations
Blood culture
Indications
Ill-appearing or toxic febrile infant
Febrile infant <60 days (per AAP sepsis evaluation pathway)
Prior to antibiotics when clinically feasible
Liver function tests
Indication
Hepatitis is a rare HHV-6 complication
Obtain if jaundice, hepatomegaly, or elevated transaminases clinically suspected
Interpretation
Mild transaminase elevation possible in primary HHV-6 infection
HHV-6 PCR (blood or CSF)
Not routinely indicated in immunocompetent children
Useful in immunocompromised patients with suspected HHV-6 reactivation
Useful in atypical presentations or CNS complications
Interpretation caveat
Chromosomally integrated HHV-6 (ciHHV-6) can give high viral loads without active infection
Clinical correlation required; ciHHV-6 occurs in ~1% of the general population
CSF analysis
Indication only if meningitis or encephalitis clinically suspected
Send for cell count, glucose, protein, Gram stain, culture, and viral PCR
CSF is typically acellular in HHV-6 CNS disease (unlike bacterial meningitis)
HHV-6 PCR of CSF
Gold standard for CNS HHV-6 infection confirmation in immunocompromised
Serology
HHV-6 IgM/IgG serology
Not practical for acute ED decision-making
Useful for retrospective confirmation in research or unclear cases
IgM rises in primary infection; IgG persists lifelong
Diagnostic Tests
Scoring Systems
Severity stratification framework
Mild (typical): High fever 3–5 days followed by maculopapular rash on defervescence
Well-appearing child
Resolution within 7–10 days
Moderate: Single simple febrile seizure
Returns to baseline within 60 minutes
No focal deficits
Severe: Febrile status epilepticus, encephalopathy, or disseminated disease
Requires inpatient management
More common in immunocompromised hosts
Febrile seizure classification
Simple febrile seizure criteria
Generalised tonic-clonic, duration <15 minutes
Single seizure within 24-hour period
Returns to full baseline
Complex febrile seizure criteria
Focal features, duration >15 minutes, or multiple within 24 hours
Does not return to baseline promptly
Warrants further evaluation including neuroimaging
MRI
MRI brain indications
HHV-6 encephalitis evaluation (gold standard modality)
Mesial temporal lobe involvement characteristic of post-transplant HHV-6 encephalitis
Limbic encephalitis pattern on fluid-attenuated inversion recovery sequences
Complex febrile seizure workup when clinically indicated
Focal deficits, prolonged post-ictal state, or recurrent focal seizures
Encephalopathy with altered mental status beyond post-ictal period
MRI preferred over CT for posterior fossa and limbic structures
MRI findings in HHV-6 encephalitis
Mesial temporal lobe hyperintensity on FLAIR
Bilateral or unilateral
Limbic structures predominantly affected
May be normal in early or mild disease
Repeat imaging if strong clinical suspicion
CT
CT head indications in roseola context
Not routinely required for uncomplicated roseola
Clinical diagnosis does not require neuroimaging
Indications for CT head
Focal neurologic deficits or focal seizure
Prolonged altered mental status (not explained by post-ictal state)
Suspected elevated intracranial pressure before LP
CT limitations
Lower sensitivity than MRI for mesial temporal and limbic involvement
Normal CT does not exclude HHV-6 encephalitis
Chest X-ray
Not routinely indicated for classic roseola
Only if prominent lower respiratory symptoms present (uncommon)
Roseola is predominantly an upper respiratory syndrome
Ultrasound
Point-of-care ultrasound indications
Volume status assessment in dehydrated child
IVC collapsibility in children able to hold still
Confirm fluid responsiveness prior to bolus
Not indicated for roseola diagnosis
No specific ultrasound findings for roseola or HHV-6
Renal ultrasound
Consideration if UTI confirmed on culture and clinical concern for pyonephrosis
Especially if fever persists beyond expected course
Not routinely ordered in the ED for roseola
Disposition
Discharge criteria
Safe discharge criteria (majority of cases)
Clinical criteria
Well-appearing child with classic rash (fever then rash sequence)
Tolerating oral fluids
No seizures, or single simple febrile seizure with return to baseline
Social criteria
Reliable caregiver present
Caregiver able to recognise return-to-ED signs
Access to follow-up
Admission indications
Definite admission criteria
Neurological emergency
Status epilepticus or complex febrile seizure not at baseline
Encephalitis or encephalopathy (altered mental status, focal deficits)
Meningitis requiring LP results and IV antibiotics pending culture
Systemic instability
Hemodynamic compromise not responding to initial resuscitation
Inability to maintain hydration orally
Toxic or ill appearance with concern for bacterial superinfection
Immunocompromised host with suspected HHV-6 disease
Antiviral therapy consideration and infectious disease input
Age-based protocols
Febrile infant <60 days
Full sepsis evaluation per AAP 2021 guidelines
Admission typically required pending blood and urine cultures
Specialist consultation triggers
Pediatric neurology
Encephalitis, encephalopathy, or febrile status epilepticus
EEG if seizure features are atypical or encephalopathy persists
Pediatric infectious disease
Immunocompromised host with suspected HHV-6 reactivation
Antiviral selection (ganciclovir vs foscarnet)
PICU
Hemodynamic instability, refractory seizures, or respiratory failure
Follow-up
Post-discharge follow-up
Discharged during febrile phase before rash appears
Routine PCP follow-up in 1–2 days
Rash will confirm roseola retrospectively
Classic resolved roseola
No follow-up needed unless complications occurred
Post-simple febrile seizure
Outpatient neurology referral if parental anxiety or recurrence
Treatment
Supportive care (mainstay)
Antipyretic therapy for comfort
Acetaminophen (paracetamol)
Dose: 15 mg/kg every 4 hours (max 5 doses per 24 hours)
Maximum single dose: 1 g
Goal is comfort, not achievement of normothermia
Ibuprofen (infants ≥6 months)
Dose: 10 mg/kg every 6–8 hours
Maximum single dose: 400 mg
Avoid in infants <6 months
Avoid aspirin in children
Risk of Reye syndrome; contraindicated
Hydration management
Oral rehydration for mild to moderate dehydration
Small frequent volumes of ORS (10 ml/kg/hour)
Breast milk or formula to continue as tolerated
IV fluid therapy if oral intake failed or moderate-severe dehydration
0.9% NaCl or Ringer's lactate 20 ml/kg bolus
Reassess response and ongoing fluid needs
Seizure management
Acute seizure treatment (active seizure)
Benzodiazepine first-line for seizure >5 minutes
Midazolam 0.1–0.2 mg/kg IN or buccal (max 5 mg)
Diazepam 0.3 mg/kg IV (max 10 mg) or 0.5 mg/kg PR (max 10 mg)
Lorazepam 0.05–0.1 mg/kg IV (max 4 mg) if IV access available
Second-line if seizure persists after 2 benzodiazepine doses
Levetiracetam 40–60 mg/kg IV (max 3 g) over 15 minutes
Fosphenytoin 20 mg PE/kg IV at 1–3 mg PE/kg/min
Post-seizure management
Simple febrile seizure
Reassurance to caregivers; no antiepileptic prophylaxis indicated
Antipyretics do not prevent recurrence of febrile seizures
Complex or prolonged seizure
Neuroimaging and neurology consultation
Consider EEG if encephalopathy features
Antiviral therapy
Immunocompetent children
Antiviral therapy not indicated
HHV-6 is resistant to acyclovir (no activity in vitro)
Ganciclovir and foscarnet not justified in self-limited illness
Immunocompromised patients with severe HHV-6 disease
Ganciclovir
Dose: 5 mg/kg IV every 12 hours
Monitoring: CBC weekly for myelosuppression
In vitro activity against HHV-6; clinical evidence primarily from transplant cohorts
Foscarnet (second-line or refractory cases)
Dose: 90 mg/kg IV every 12 hours or 60 mg/kg IV every 8 hours
Monitoring: Renal function and electrolytes (nephrotoxic, causes dyselectrolytemia)
Used in ganciclovir-resistant or intolerant patients
Combination ganciclovir and foscarnet
For refractory post-transplant HHV-6 encephalitis
Infectious disease consultation required
Antibiotics
Antibiotics not routinely indicated for roseola
Bacterial superinfection is rare; diagnosis of roseola is viral
Review and stop empiric antibiotics if initiated during the febrile phase once rash confirms roseola
Antibiotics indicated if
Concurrent confirmed bacterial infection (UTI, AOM with clinical criteria)
Sepsis workup positive for bacterial source
Special Populations
Pregnancy
Maternal HHV-6 primary infection in pregnancy
HHV-6 reactivation during pregnancy
Seroprevalence in pregnant women >95%; primary infection in pregnancy is rare
Reactivation during pregnancy has been associated with adverse fetal outcomes in small case series
Fetal and neonatal considerations
Congenital HHV-6 infection via chromosomally integrated HHV-6 (ciHHV-6) is well-described
ciHHV-6 is inherited; present in every cell; associated with developmental and neurological concerns under investigation
Antiviral considerations in pregnancy
No approved antiviral regimen for HHV-6 in pregnancy
Ganciclovir is teratogenic in animals; use only if maternal benefit outweighs risk
Infectious disease and maternal-fetal medicine consultation required
Geriatric
HHV-6 in older adults
Primary roseola is extremely rare in adults; almost all adults are seropositive
Over 95% of adults carry latent HHV-6 from childhood primary infection
HHV-6 reactivation in elderly or immunocompromised adults
Limbic encephalitis and drug-induced hypersensitivity syndrome (DIHS/DRESS) are recognized reactivation syndromes
Drug reaction with eosinophilia and systemic symptoms (DRESS): fever, rash, organ involvement 2–8 weeks after drug exposure
HHV-6 in elderly transplant recipients
Post-transplant encephalitis risk parallels that in younger immunocompromised patients
Ganciclovir or foscarnet as per adult dosing with renal function adjustment
Pediatrics
Typical age and clinical course
Peak incidence 6–15 months
Accounts for ~10% of ED visits for acute febrile illness in children <2 years
20% of such visits in 6–12 month age group
Self-limited course
Complete resolution within 7–10 days in immunocompetent children
No long-term sequelae in typical disease
Febrile seizure management in pediatrics
Simple febrile seizures: no antiepileptic prophylaxis
Recurrence risk ~30% with subsequent febrile illnesses
Risk not reduced by antipyretics or prophylactic anticonvulsants
HHV-6 associated febrile status epilepticus
HHV-6B-infected children more likely to develop status epilepticus vs other febrile seizure causes
Requires aggressive benzodiazepine management and hospital admission
Neonates and young infants
Roseola is rare in infants <3 months due to residual maternal antibody protection
Febrile neonates <60 days require full sepsis evaluation regardless
AAP 2021 febrile infant pathway applies
Weight-based dosing reference
Acetaminophen: 15 mg/kg per dose PO
Maximum 75 mg/kg per day
Ibuprofen (≥6 months): 10 mg/kg per dose PO
Maximum 40 mg/kg per day
Midazolam IN: 0.2 mg/kg (max 5 mg per dose)
Diazepam IV: 0.3 mg/kg (max 10 mg per dose)
Background
Epidemiology
Incidence and prevalence
Seroprevalence: >95% of children are HHV-6B seropositive by age 2
Peak incidence age 6–15 months (waning maternal antibody window)
Over 95% of adults carry latent HHV-6 from prior childhood infection
ED burden
Roseola accounts for ~10% of all ED visits for febrile illness in children <2 years
In 6–12 month olds: ~20% of febrile ED visits
Seizure burden
HHV-6 causes ~8–13% of primary febrile seizures
HHV-6 accounts for one-third of all febrile seizures in children ≤2 years
Causative agents
HHV-6B: ~90% of roseola cases
Betaherpesvirus subfamily; roseolovirus genus
HHV-7: minority of cases; typically presents slightly later (18–36 months)
Second episodes of roseola often due to HHV-7 after prior HHV-6B infection
Chromosomally integrated HHV-6 (ciHHV-6)
Occurs in ~1% of the general population
Viral DNA integrated in every cell
High viral loads on PCR without active infection; clinical correlation required
Pathophysiology
Primary infection mechanism
Transmission via saliva from asymptomatic shedders
HHV-6 actively shed in saliva of healthy adults
No strict seasonal predilection; occurs year-round
Viral tropism
HHV-6 primarily infects CD4+ T lymphocytes
Also infects monocytes, macrophages, dendritic cells, and CNS astrocytes
Latency established in bone marrow progenitor cells, monocytes, and brain
Fever and rash mechanism
Febrile phase (days 0–4): primary viraemia and immune activation
High-level viral replication with cytokine release (IL-6, TNF-alpha)
Leukopenia and lymphopenia due to T-lymphocyte infection and depletion
Rash phase (day 4–7): immune-mediated response
Rash appears as viral replication controlled and fever resolves
Immune complex deposition and T-cell mediated dermal response
CNS involvement mechanism
HHV-6 neurotropism
Infects astrocytes and neurons, particularly in limbic structures
Febrile seizures: cytokine-mediated lowering of seizure threshold
Encephalitis: direct viral invasion of CNS parenchyma
Bulging fontanelle mechanism
Inflammatory oedema and transient CSF pressure increase
Occurs in ~26%; does not consistently reflect meningeal infection
Reactivation biology
HHV-6 reactivates with immunosuppression
Post-transplant setting: most clinically significant reactivation syndrome
Triggers include corticosteroids, anti-rejection therapy, graft manipulation
Can cause encephalitis, pneumonitis, bone marrow suppression, hepatitis
Therapeutic Considerations
Rationale for supportive-only management in immunocompetent children
Self-limited illness with excellent prognosis
No antiviral demonstrates benefit in immunocompetent host
HHV-6 intrinsically resistant to acyclovir (lacks thymidine kinase substrate)
Ganciclovir mechanism and limitations
Inhibits HHV-6 DNA polymerase; in vitro activity confirmed
Clinical evidence limited to small transplant cohort studies
Bone marrow toxicity limits use in non-life-threatening illness
Antipyretic evidence base
Antipyretics reduce discomfort but do not prevent febrile seizures
AAP 2011 guidance: treat fever for comfort, not normothermia
No study demonstrates febrile seizure prevention with scheduled antipyretics
Febrile seizure prophylaxis evidence
No role for antiepileptic prophylaxis after simple febrile seizure
Risk-benefit ratio unfavourable; recurrence risk (~30%) does not justify prophylaxis
Complex or status epilepticus: neurological consultation for individualised plan
Patient Discharge Instructions
copy discharge instructions
What your child has
Your child has roseola, a common and harmless viral infection caused by human herpesvirus 6
It causes several days of high fever followed by a pink rash when the fever breaks
The rash is a sign that your child is getting better, not getting worse
Roseola is self-limited and resolves completely in 7–10 days without complications in healthy children
No specific treatment is needed beyond fever and comfort management
Home care instructions
Fever management
Give acetaminophen (paracetamol) 15 mg/kg every 4–6 hours for comfort if needed
Give ibuprofen 10 mg/kg every 6–8 hours for children 6 months and older
Do not give aspirin to children (risk of Reye syndrome)
Hydration
Encourage frequent small amounts of clear fluids, breastmilk, or formula
If diarrhea present, use an oral rehydration solution (Pedialyte or equivalent)
Activity
No restrictions once fever has resolved; the rash alone is not contagious
Child was most contagious during the febrile phase before the rash appeared
Return to emergency department immediately if
Seizure of any kind, or seizure lasting longer than 5 minutes
Call 911 if seizure does not stop within 5 minutes
Lethargy, difficulty to wake, or unresponsiveness
Bulging fontanelle combined with extreme irritability or stiff neck
High fever persisting beyond 5–6 days or returning after defervescence
Non-blanching rash (purple or red spots that do not turn white when pressed)
Unable to keep fluids down or signs of dehydration
No tears when crying
No wet diapers for more than 8 hours
Sunken eyes or fontanelle
Looks progressively more unwell or you are worried
Daycare and isolation guidance
Child may return to daycare once fever-free for 24 hours
The rash is not a contraindication to return to daycare
Siblings and household contacts who are healthy do not require prophylaxis
Immunocompromised household members should consult their physician
References
Guidelines and key sources
Hall CB et al. Human herpesvirus-6 infection in children: a prospective study of complications and reactivation. New England Journal of Medicine. 1994
Landmark NEJM prospective study establishing clinical features and ED diagnosis patterns
Most common ED diagnoses were "fever with otitis" (30%) and "fever of undetermined cause" (29%)
Stone RC, Micali GA, Schwartz RA. Roseola infantum and its causal human herpesviruses. International Journal of Dermatology. 2014
Comprehensive clinical review including epidemiology, fever duration, and rash characteristics
Asano Y et al. Clinical features of infants with primary human herpesvirus 6 infection. Pediatrics. 1994
Clinical feature prevalence data including febrile seizure rates and exam findings
Suga S et al. Clinical and virological analyses of 21 infants with exanthem subitum and CNS complications. Annals of Neurology. 1993
CNS complication characterisation including bulging fontanelle (26%) and encephalitis
Tembo J et al. Children infected by HHV-6B with febrile seizures are more likely to develop febrile status epilepticus. Journal of Medical Virology. 2018
HHV-6B and febrile status epilepticus risk compared to other fever causes
Tesini BL, Epstein LG, Caserta MT. Clinical impact of primary infection with roseoloviruses. Current Opinion in Virology. 2014
Antiviral therapy review including ganciclovir and foscarnet evidence
Sullivan JE, Farrar HC. Fever and antipyretic use in children. Pediatrics. 2011
AAP policy statement: antipyretics for comfort, not normothermia; no seizure prevention
Pantell RH et al. Evaluation and management of well-appearing febrile infants 8 to 60 days old. Pediatrics. 2021
AAP 2021 febrile infant guideline applicable to roseola pre-eruptive phase in young infants
Smith DK, Sadler KP, Benedum M. Febrile seizures: risks, evaluation, and prognosis. American Family Physician. 2019
Simple febrile seizure management: no prophylaxis; recurrence risk ~30%
Cristoforo T et al. The not-so-soft spot: pathophysiology of the bulging fontanelle in association with roseola. Pediatric Emergency Care. 2020
Bulging fontanelle in roseola: benign mechanism versus meningitis differentiation
Agut H, Bonnafous P, Gautheret-Dejean A. Human herpesviruses 6A, 6B, and 7. Microbiology Spectrum. 2016
Comprehensive virology review including reactivation biology and antiviral susceptibility
Pellett PE et al. Chromosomally integrated human herpesvirus 6: questions and answers. Reviews in Medical Virology. 2012
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.